The individual was instructed to stop semaglutide and start dulaglutide once-weekly subcutaneous injections. No nodules happen to be described within the five months For the reason that patient stopped semaglutide and started dulaglutide.Monitor renal functionality when initiating or escalating doses of WEGOVY in patients reporting critical adverse